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BRCA1 and 53BP1 play decisive roles in the choice of DNA double-strand break repair mechanisms. BRCA1 promotes
DNA end resection and homologous recombination (HR) during S/G2 phases of the cell cycle, while 53BP1 inhibits end
resection and facilitates non-homologous end-joining (NHEJ), primarily during G1. This competitive relationship is critical
for genome integrity during cell division. However, their relationship in the many cells in our body that are not cycling is
unknown. We discovered profound differences in 53BP1 and BRCA1 regulation between cycling and non-cycling cells.
Cellular growth arrest results in transcriptional downregulation of BRCA1 and activation of cathepsin-L (CTSL)-mediated
degradation of 53BP1. Accordingly, growth-arrested cells do not form BRCA1 or 53BP1 ionizing radiation-induced foci
(IRIF). Interestingly, cell cycle re-entry reverts this scenario, with upregulation of BRCA1, downregulation of CTSL, stabilization of 53BP1, and 53BP1 IRIF formation throughout the cycle, indicating that BRCA1 and 53BP1 are important in
replicating cells and dispensable in non-cycling cells. We show that CTSL-mediated degradation of 53BP1, previously
associated with aggressive breast cancers, is an endogenous mechanism of non-cycling cells to balance NHEJ (53BP1)
and HR (BRCA1). Breast cancer cells exploit this mechanism to ensure genome stability and viability, providing an opportunity for targeted therapy.

Introduction
The tumor suppressor proteins 53BP1 and BRCA1 have
emerged as key regulators of the choice between DNA doublestrand break (DSB) repair mechanisms.1-5 Recruitment of BRCA1
to DSBs promotes the DNA end resection that is necessary for
homologous recombination (HR),6 a mechanism that repairs
DNA with great fidelity using sister chromatids as templates for
recombination.7 In contrast, 53BP1 binding to DSBs inhibits end
resection and facilitates non-homologous end joining (NHEJ),
which is considered an error-prone mechanism of DNA repair.
A number of studies have addressed the functional relationship
between 53BP1 and BRCA1 during the cell cycle in an attempt
to understand the contribution of HR and NHEJ to the repair
of DNA DSBs at different phases of the cell cycle.8-10 Some studies proposed that HR is the preferred mechanism of DSB repair
during S and G2 phases of the cell cycle, while NHEJ functions
throughout the cell cycle, being dominant in G1. In HR-deficient
cells, NHEJ can repair up to 85% of DSBs in G2, supporting

the notion that these 2 pathways compete for repair substrate.11-14
Initial studies showed high levels of BRCA1 in exponentially
growing cells, which decreased dramatically upon growth factor withdrawal and arrest in G0 /G1,15-17 and a progressive upregulation of BRCA1 and formation of BRCA1/CtIP/MRN DNA
repair complexes as cells re-entered the cell cycle.18 These data
suggested that the regulation of BRCA1 levels during the cell
cycle could be responsible for favoring 53BP1-dependent NHEJ
during G1 and HR during S and G2 phases of the cell cycle.
However, recent studies using time-lapse microscopy and
fluorescent reporters to monitor DSBs in asynchronous cycling
cells have challenged this notion. One study confirmed that
early in G1, cells repair DSBs exclusively by NHEJ.19 However,
cells damaged toward the end of G1 activate HR, which is most
active coinciding with the highest levels of replication during S
phase. Cells damaged during late S and G2 exhibit both HR and
NHEJ. These findings revealed a relationship between the levels of active replication and HR and indicated that NHEJ is the
dominant repair mechanism during G1 and G2 phases. Another
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in the BRCA1 gene. Altogether, these studies demonstrate a key
role for CTSL in the regulation of 53BP1 protein levels, thus
supporting the notion that inhibition of CTSL-mediated degradation of 53BP1 could represent a new therapeutic strategy for
breast cancers with the poorest prognosis, as well as some laminrelated diseases.
Despite these recent findings, many questions still remain
about the regulation of 53BP1 levels and the functional relationship between 53BP1 and BRCA1 during the cell cycle. In addition, the regulation of these proteins in the many cells in the
body that are not cycling remains obscure. Here, we monitored
the regulation of 53BP1 levels during exit and re-entry into the
cell cycle. We find changes in global levels of 53BP1 protein during growth arrest that mirror BRCA1 expression, and that are
regulated by CTSL. Importantly, our study reveals profound differences in the regulation of BRCA1 and 53BP1 proteins between
cycling and non-cycling cells.

Results
Inverse correlation between CTSL and levels of 53BP1 and
BRCA1 proteins in growth-arrested human fibroblasts
Previous studies showed that BRCA1 expression increases as
cells progress through the G1 phase of the cell cycle, peak during S phase, and remain elevated at the G2 /M transition.15-17 In
contrast, a recent study showed that the levels of BRCA1 do not
change during the cell cycle.20 Thus, whether or not BRCA1
levels are regulated during the cell cycle remains controversial.
Similarly, how the levels of 53BP1 are regulated during the cell
cycle or during growth arrest is not known. Given our previous
finding that CTSL regulates 53BP1 stability,27-29 we investigated a
possible relationship between CTSL and 53BP1 levels in growtharrested and cycling cells by using human fibroblasts immortalized with telomerase (BJ + hTert), which have intact cell cycle
regulation and growth arrest by contact inhibition. BJ + hTert
fibroblasts were plated at high confluency and maintained confluent for 72 h to induce growth arrest. At this point, cells were
either collected, or replated at low density to allow re-entry into
the cell cycle. Samples of cells were collected at different times
after re-entry into the cell cycle. We monitored the cell cycle distribution profile at each condition via propidium iodide content.
As shown in Figure 1A, asynchronously growing cells show a
normal cell cycle profile, while contact inhibited cells accumulate at G0 /G1 phase. To determine if confluency arrests cells in
G0 or G1, we monitored the presence of Ki67, a marker that is
absent in cells arrested in G0. As shown in Figure S1, most of the
cells arrested by confluency are positive for Ki67, indicating that
cells arrest primarily in G1. Figure 1A also shows that approximately 24 h after re-plating, cells had re-entered the cell cycle and
showed a normal cell cycle distribution profile.
Next, we monitored the levels of BRCA1, CTSL, and 53BP1
during growth arrest and at different times after re-entry into
the cell cycle and compared the levels of these proteins to those
of asynchronously growing cells (Fig. 1B, left panels). Arrest in
G1 is accompanied by a profound increase in the levels of CTSL
and a decrease in 53BP1 protein compared with asynchronously
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study has provided mechanistic insights about the functional
antagonistic relationship between these 2 DNA repair pathways
in cycling cells.20 The model proposed is somewhat different
from the previous study, showing that BRCA1 in complex with
CtIP promotes end resection of the DSB, while antagonizing the
binding of a complex formed by 53BP1 and Rif1 to the break
during S and G2 phases of the cell cycle. Inhibition of 53BP1/
Rif1 recruitment requires CDK-mediated phosphorylation of
CtIP. In turn, recruitment of the 53BP1/Rif1 complex, which
requires ATM-dependent phosphorylation of 53BP1 N terminus,
inhibits the recruitment of the BRCA1/CtIP complex during G1.
This study proposed a cell cycle-regulated circuit whereby the
recruitment of BRCA1/CtIP or 53BP1/Rif1 complexes regulate
DNA DSB repair pathway choice to ensure predominance of
NHEJ during G1 and of HR during S and G2 phases of the cell
cycle. Importantly, the latter study reported that the global levels
of BRCA1 do not change during the cell cycle.20
Although the specific contributions of BRCA1 and 53BP1 to
DNA repair mechanisms during the cell cycle remain controversial, it is well accepted that a balance between BRCA1 and
53BP1 is important for the maintenance of genome integrity.
Accordingly, different lines of evidence have associated loss of
either of these proteins with accumulation of DNA damage and
genomic instability and with increased cancer incidence.21-25
Interestingly, 53BP1 proficiency seems to play a major role in the
profound genomic instability that results from BRCA1 deficiency.
Recent groundbreaking studies demonstrated that loss of 53BP1
is synthetically viable with the loss of BRCA1.1-5 Loss of 53BP1
in the context of BRCA1 deficiency allows end resection and
partially rescues HR defects. Interestingly, loss of 53BP1 rescued
embryonic lethality in BRCA1-deficient mice (BRCA1Δ11/Δ11).
Furthermore, reduced levels of 53BP1 were observed in breast
cancers with the poorest prognosis, such as BRCA1-mutated and
triple-negative (TNBC). Overall, these studies suggest that loss
of 53BP1 contributes to tumor progression, especially in those
tumors that present HR deficiencies.
The mechanisms responsible for regulating 53BP1 protein
levels in normal cells or downregulating 53BP1 in tumor cells
remain poorly understood. Our previous studies identified one
mechanism modulating the levels of 53BP1 protein in mammalian cells. Initially, we found that depletion of the structural
nuclear proteins A-type lamins activate the degradation of 53BP1
by the cysteine protease cathepsin L (CTSL), which translocates
into the nucleus in lamins-deficient cells.26,27 Accordingly, depletion or inhibition of CTSL activity rescued the levels of 53BP1, as
well as the defects in NHEJ and the genomic instability observed
in lamins-deficient cells.28,29 Most recently, we found that CTSLmediated degradation of 53BP1 is activated upon depletion of
BRCA1 in breast cancer cells, which allows BRCA1-deficient
cells to rescue HR and overcome genomic instability and growth
arrest.30 Interestingly, inhibition of CTSL stabilized 53BP1 protein in the context of BRCA1 deficiency and increased the sensitivity of BRCA1-deficient cells to DNA damaging strategies.
Importantly, we also found an inverse linear correlation between
nuclear levels of CTSL and 53BP1 in breast tumors from patients
with sporadic TNBC and patients carrying germline mutations

levels of Cyclin A throughout the course of the experiment were
monitored as an additional indicator of cell cycle progression, as
Cyclin A is markedly reduced in G1 phase. We monitored levels of
A-type lamins (Lamin A/C) as loading control. The data demonstrate that 53BP1 protein levels fluctuate during exit and re-entry
into the cell cycle, mirroring the levels of BRCA1, and that CTSL
inversely correlates with the levels of both proteins.
To determine whether CTSL contributes to 53BP1 downregulation in growth-arrested cells, we inhibited CTSL activity in
BJ + hTert fibroblasts via treatment with the cathepsin inhibitor
E64 (10 μM) throughout the time course of the experiment. As
shown in Figure 1C, treatment with E64 did not modify the

Figure 1. Differences in the levels of DNA repair factors between growth-arrested and cycling human fibroblasts. (A) Cell cycle profile of human fibroblasts expressing telomerase (BJ + hTERT) either growing asynchronously, growth arrested by contact inhibition, or released from the growth arrest.
Cells were fixed and labeled with propidium iodide and analyzed for fluorescent DNA content using the Nexcelom Cellometer. The percentage of cells in
G0/G1, S, and G2/M phases of the cell cycle is shown under each cell cycle profile. (B) Western blots to monitor the levels of the protease cathepsin L (CTSL),
DNA repair factors (53BP1, BRCA1, RPA), cell cycle regulators (Cyclin A, p107), and loading control Lamin A/C in growth-arrested and cycling fibroblasts
treated with cathepsin inhibitor E64 or vehicle control. Note the marked increase in CTSL and the decrease in 53BP1 and BRCA1 levels in growth-arrested
cells and how E64 treatment prevents 53BP1 decrease. (C) Cell cycle profile monitored as in (A) but in cells incubated with 10 μM E64 throughout the
time course of the experiment. (D) Western blots in cells treated with E64 to monitor the same proteins as in (B). Note how inhibition of cathepsin activity
with E64 prevents the decrease in 53BP1 protein levels. Representative experiments of at least 3 biological repeats are shown.
www.landesbioscience.com
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growing cells. We also observed decreased BRCA1 levels in
growth-arrested cells, confirming previous results. As cells
re-entered the cell cycle, a reduction in CTSL correlated with
increased 53BP1 and BRCA1 protein levels. Consistent with
the decrease in CTSL levels upon re-entry into the cell cycle,
cathepsin L activity was reduced as early as 16 h post-release
from growth arrest (Fig. S2). In contrast, we found that the levels of the single-strand DNA-binding protein RPA remain constant during exit and re-entry into the cell cycle. In addition,
we show that the Rb family member p107 also mirror 53BP1
and BRCA1 expression, with low levels in growth-arrested cells,
which increase as cells re-enter the cell cycle. Changes in the

3632

and BRCA1 proteins are recruited to sites of DNA damage,
forming ionizing radiation-induced foci (IRIF). Figure 3A shows
representative images of BRCA1 content in growth-arrested and
asynchronous fibroblasts in the absence of ionizing radiation. In
growth-arrested cells, BRCA1-positive cells are rarely observed.
In contrast, cells positive for BRCA1 are readily observed in asynchronously growing cells, as expected. Interestingly, the few cells

©2013 Landes Bioscience. Do not distribute.

cell cycle profile at any of the conditions tested. Interestingly,
we found that E64 treatment prevented the decrease of 53BP1 in
contact-inhibited cells (Fig. 1B, right panels). In contrast, E64
had no effect on the levels of 53BP1 or any of the other proteins
tested in asynchronously growing cells or in cells that re-entered
the cell cycle. These results indicate that CTSL participates in
the regulation of 53BP1 levels specifically in fibroblasts arrested
in G1 by contact inhibition.
Transcriptional regulation of CTSL, 53BP1, and BRCA1 in
growth-arrested fibroblasts
The above results show profound changes in the levels of
CTSL, 53BP1, and BRCA1 proteins during exit and re-entry into
the cell cycle and demonstrate a role for CTSL in the regulation of
53BP1 levels. Here, we determined whether any of these changes
are due to transcriptional regulation of the genes. We performed
qRT-PCR in BJ + hTert fibroblasts growing asynchronously,
growth arrested by contact inhibition, or allowed to re-enter the
cell cycle. We compared the levels of CTSL, 53BP1, and BRCA1
transcripts between cells treated with vehicle control (H2O), or
with E64 to inhibit cathepsin activity. As shown in Figure 2A,
the levels of BRCA1 transcripts are markedly decreased in contact-inhibited cells and progressively increase as cells re-enter
the cell cycle, consistent with previous reports. Importantly, we
found that the levels of BRCA1 transcripts are not affected by
inhibition of CTSL activity at any condition tested. In contrast,
we observed a significant upregulation of CTSL transcripts in
growth-arrested cells (Fig. 2B). Treatment with E64 did not have
a profound effect in the levels of CTSL transcripts throughout
the time course of the experiment. Thus, the levels of BRCA1
and CTSL transcripts correlate with proteins levels, indicating that both proteins are regulated transcriptionally during
growth arrest. Interestingly, we found that the levels of 53BP1
transcripts remain constant upon contact inhibition (Fig. 2C),
despite the marked decrease in 53BP1 protein (Fig. 1B, left panels). Furthermore, treatment with E64 does not alter the levels
of 53BP1 transcripts during growth arrest, although it stabilizes
the levels of 53BP1 protein (Fig. 1B, right panels). These results
indicate that 53BP1 protein stability is regulated during growth
arrest, and that CTSL plays a major role in the degradation of
53BP1. Intriguingly, we also found that inhibition of CTSL by
E64 treatment results in a consistent downregulation of 53BP1
transcripts levels as cells re-enter the cell cycle. However, these
changes in transcription do not translate into decreased 53BP1
protein levels. These results suggest that CTSL impacts on 53BP1
expression at different levels. On one hand, CTSL activity mediates degradation of 53BP1 protein in growth-arrested cells while
maintaining 53BP1 transcripts levels in cycling cells.
Formation of 53BP1 and BRCA1 IRIF in growth-arrested
and cycling fibroblasts
The decrease in global levels of 53BP1 and BRCA1 shown
above suggests that growth-arrested fibroblasts could be compromised in their ability to accumulate these DNA repair factors
at sites of DNA damage. To test this hypothesis, we performed
immunofluorescence (IF) with 53BP1 and BRCA1 antibodies in
cells contact-inhibited and cells growing asynchronously that are
irradiated with 8 Gy or mock irradiated. Upon irradiation, 53BP1

Figure 2. Transcripts levels of BRCA1, CTSL, and 53BP1 in growth-arrested
and cycling human fibroblasts. (A) Quantitation of BRCA1 transcripts levels by qRT-PCR in human fibroblasts expressing telomerase (BJ + hTERT)
either growing asynchronously, growth arrested by contact inhibition,
or released from the growth arrest. Relative expression is compared in all
conditions between cells incubated in water as control and cells incubated
with 10 μM E64. (B) Quantitation of CTSL transcripts levels as in (A). (C)
Quantitation of 53BP1 transcripts levels as in (A). **Represents P value of
statistical significance (P ≤ 0.05) of that sample compared with all the other
samples in the experiment. The complete statistical analysis of all the samples under the different conditions is shown in supplemental information.
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BRCA1 intensity in arrested cells. Next, we compared the formation of BRCA1 IRIF between growth-arrested and asynchronously growing cells (Fig. 3B). We found that a high percentage
of asynchronously growing cells present with BRCA1 IRIF. In
contrast, only a few growth-arrrested cells present with BRCA1
IRIF, consistent with the global decrease of BRCA1 protein levels

©2013 Landes Bioscience. Do not distribute.

positive for BRCA1 consistently showed higher label intensity
with DAPI, indicating that these cells have higher DNA content,
thus representing a post-replication stage of the cell cycle (S or G2
phases). The graph in Figure 3A shows the quantitation of global
BRCA1 fluorescence intensity in asynchronous and growtharrested cells. We found a statistically significant decrease in

Figure 3. Levels of BRCA1 and 53BP1 and formation of IRIF in growth-arrested and cycling cells. (A) Immunofluorescence with BRCA1 antibody was performed in asynchronous and contact-inhibited cells that were mock irradiated. DAPI staining was used to identify all nuclei. Graph shows quantitation
of the intensity of fluorescence (relative fluorescence units) in 200 cells per condition. (B) IF with BRCA1 antibody in cells of the same growth conditions
as (A) after irradiation with 8 Gy. Note the decrease in BRCA1 intensity of fluorescence, both in control and irradiated growth-arrested cells. (C) The same
experiments as in (A) were performed with 53BP1 antibody. (D) The same experiments as in (B) were performed with 53BP1 antibody. Note how 53BP1
levels mirror BRCA1 in all conditions tested, with low levels of 53BP1 in growth-arrested cells irradiated and control. *Represents P value of statistical
significance (P ≤ 0.05).
www.landesbioscience.com
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were irradiated with 8 Gy. Statistically significant differences were not observed (NS).
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in these cells. As a consequence, the global intensity of BRCA1 growth arrested by serum deprivation exhibit high levels of
fluorescence is markedly decreased in irradiated arrested fibro- CTSL and low levels of BRCA1 and 53BP1.30 Here, we deterblasts. Thus, non-cycling fibroblasts are unable to form BRCA1 mined whether CTSL is responsible for the decrease of 53BP1 in
foci after IR.
these cells. MCF7 cells were lentivirally transduced with shRNA
In addition, we compared the content of 53BP1 between specific for depletion of CTSL (shCTSL) or shRNA control
growth-arrested and asynchronously growing fibroblasts by IF in (shscr). Both cell lines were grown in complete media or media
the absence of IR. As shown in Figure 3C, growth-arrested fibro- with 0.1% serum (starved) for 48 h and either collected immeblasts show a marked decrease in the intensity of labeling with diately, or re-plated in complete media containing 10% serum
53BP1 antibody, consistent with the decrease in the global levels to allow re-entry into the cell cycle. Figure 5A shows the cell
of the protein. Similarly, we found a striking difference in the cycle profile of cells subjected to the different treatments assessed
intensity of 53BP1 IRIF between growth-arrested and asynchro- by propidium iodide staining. Serum deprivation led to growth
nously growing cells (Fig. 3D). We confirmed the specificity of arrest of MCF7 cells, and approximately 24 h post-release, cells
the antibody by performing immunofluorescence and immuno- exhibit a normal cell cycle profile. Subsequently, we monitored
histochemistry in cells depleted of 53BP1 via lentiviral transduc- the levels of 53BP1, BRCA1, and CTSL proteins throughtion with shRNA (Fig. S3). Overall, the data demonstrate that out the time course of the experiment. As shown in Figure 5B
non-cycling cells do not accumulate 53BP1 at DNA repair foci.
(left panels), growth arrest by serum starvation of MCF7 cells
Next, we tested whether activation of CTSL-mediated deg- proficient in CTSL leads to a marked decrease in the levels of
radation of 53BP1 is specific of G1-arrested cells, or if it is also a BRCA1 and 53BP1 proteins, concomitant with an increase in
characteristic of the G1 phase in cycling cells. We took advantage CTSL protein, as previously reported.30 In addition, an increase
of the fact that cyclin A is absent in this phase of the cell cycle. in 53BP1 and BRCA1 protein levels are observed upon re-entry
Thus, we performed dual immunofluorescence with cyclin A and of MCF7 cells into the cell cycle. Thus, exit and re-entry into the
53BP1 antibodies in asynchronous cells control or irradiated with cell cycle of MCF7 cells recapitulates the phenotype observed
8 Gy. As shown in Figure 4, cells positive and negative for cyclin in BJ + hTert fibroblasts, indicating that this is a phenomenon
A present with similar global levels of 53BP1. In addition, cells induced by different types of growth arrest and in different cell
in the G1 phase of the cell cycle (cyclin A-negative) were able to types. Interestingly, we find that depletion of CTSL prevents the
form 53BP1 IRIF with the same intensity as cells in S/G2 phases decrease of 53BP1 in serum-starved MCF7 cells (Fig. 5B, right
of the cell cycle (cyclin A-positive), as assessed by quantitation panels), indicating that CTSL is responsible for the decrease in
of intensity of fluorescence (graph). These results are consistent 53BP1 protein in this context. Importantly, depletion of CTSL
with previous studies showing that 53BP1 IRIF can form in does not affect the cell cycle profile at any of the conditions tested
all phases of the cell cycle.19,20,31 However, one study in hTert- (Fig. 5C). In contrast, the levels of BRCA1 were unaffected by
immortalized retinal pigment epithelial cells (RPE1), showed the loss of CTSL, showing a decrease in growth-arrested cells.
expression of 53BP1 in cells growth
arrested by serum deprivation.32 This
discrepancy suggests that different cell
lines might regulate 53BP1 in a distinct manner. Whether or not growtharrested hTert-RPE1 cells can activate
CTSL remains unknown. Overall, our
data demonstrate profound differences
in the regulation of 53BP1 between
cycling and non-cycling human fibroblasts. Non-cycling fibroblasts activate CTSL-mediated degradation of
53BP1, while cycling fibroblasts maintain constant levels of 53BP1 throughout the cell cycle.
Inverse correlation between CTSL
and levels of 53BP1 and BRCA1 proteins in serum-starved MCF7 cells
Our results indicate that BJ + hTert
fibroblasts growth arrested in G1
Figure 4. Levels of 53BP1 and formation of IRIF in cycling cells. Immunofluorescence with 53BP1 and
by contact inhibition transcriptionCyclin A antibodies was performed in asynchronously growing cells that were irradiated with 8 Gy or
ally downregulate BRCA1 and actimock irradiated. DAPI staining was used to identify all nuclei. Cyclin A positive cells represent cells in S/
vate CTSL-mediated degradation
G2 phases of the cell cycle, while Cyclin A-negative cells represent cells in G1. Graphs show quantitation
of the intensity of fluorescence (relative fluorescence units) in 200 cells per condition. We compared
of 53BP1. Our previous studies had
intensity of fluorescence of 53BP1 between Cyclin A-positive (S/G2) and Cyclin A-negative (G1) cells that
shown that breast cancer cells (MCF7)

genes. We also compared transcripts levels between MCF7 cells
proficient and deficient in CTSL. We performed qRT-PCR in
MCF7 cells growing asynchronously, cells growth arrested by
serum starvation, and cells that re-entered the cell cycle. As shown
in Figure 6A, serum starvation leads to a statistically significant
downregulation of BRCA1 transcripts levels, consistent with the
decrease in BRCA1 protein, and recapitulating the phenotype of
fibroblasts growth arrested by contact inhibition. In addition,
we found an upregulation of BRCA1 transcripts as MCF7 cells
re-entered the cell cycle, also consistent with the results in fibroblasts. Importantly, depletion of CTSL did not affect the levels
of BRCA1 transcripts at any of the conditions tested, indicating

Figure 5. Differences in the levels of DNA repair factors between growth-arrested and cycling breast cancer cells. (A) Cell cycle profile of breast cancer
cells (MCF7) either growing asynchronously, growth arrested by serum deprivation (starved), or released from the growth arrest by serum supplementation. Cells were fixed and labeled with propidium iodide and analyzed for fluorescent DNA content using the Nexcelom Cellometer. The percentage of
cells in G0/G1, S, and G2/M phases of the cell cycle is shown under each cell cycle profile. (B) Western blots to monitor the levels of the protease cathepsin L (CTSL), DNA repair factors (53BP1, BRCA1, and RPA), and cell cycle regulators (Cyclin A, p107) in MCF7 cells proficient or deficient in CTSL (shscr
and shCTSL, respectively). Note the increase in CTSL and the marked decrease in 53BP1 and BRCA1 levels in growth-arrested cells. (C) Cell cycle profile
monitored as in (A), but in MCF7 cells depleted of CTSL via lentiviral transduction with a specific shRNA (shCTSL). The blots shown in (B) represent the
same experiment and thus levels of all proteins can be compared. Note how depletion of cathepsin L prevents the decrease in 53BP1 protein levels.
Representative experiments of at least 3 biological repeats are shown.
www.landesbioscience.com
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Consistent with observations in BJ + hTert fibroblasts, the levels
of RPA were constant throughout the cell cycle, and the levels of
Cyclin A and p107 were downregulated in growth-arrested cells.
Altogether, our results demonstrate that CTSL plays a role in the
regulation of 53BP1 protein levels in growth-arrested cells, allowing 53BP1 protein levels to mirror levels of BRCA1 throughout
the cell cycle.
Transcriptional regulation of CTSL, 53BP1, and BRCA1
during growth arrest in MCF7 cells
Here, we determined whether the changes in CTSL, 53BP1,
and BRCA1 protein levels observed in MCF7 cells during the cell
cycle correlate with levels of transcription of the corresponding

and by different means. Importantly, treatment of MCF7 cells
with hydroxyurea (HU) to inhibit DNA replication and arrest
cells in S phase does not lead to downregulation of BRCA1 or
activation of CTSL-mediated degradation of 53BP1 (Fig. 6D).
Rather, increased levels of 53BP1 and BRCA1 proteins are
observed in HU-treated MCF7 cells. These results suggest that
the decrease of 53BP1 and BRCA1 proteins is specific to growth
arrest prior to replication.

Discussion
There is substantial evidence that NHEJ is active in all
phases of the cell cycle, while HR is particularly important in S/
G2 phases.12 Some studies have shown that BRCA1 levels fluctuate during the cell cycle and markedly increase during S/G2
phases,16,17 while others have reported constant levels of BRCA1
during the cell cycle.20 Recent elegant studies in asynchronously
growing cells proposed the notion of a cell cycle-regulated circuit, whereby the recruitment of BRCA1/CtIP or 53BP1/Rif1
complexes regulate the choice of DNA DSB repair pathway
during the cell cycle.20 In this model, the choice of mechanism
of DNA repair is regulated by recruitment, not by changes in
the levels of the proteins/complexes in cycling cells. The present study investigated whether a similar functional relationship
exists in non-cycling cells, which is a state of many cells in the
body that are not dividing, but that are poised to respond to
proliferation stimuli. We find profound differences in the regulation of 53BP1 and BRCA1 between cycling and non-cycling
cells. Growth-arrested cells exhibit a marked downregulation of
BRCA1 transcripts and protein levels as well as upregulation of
CTSL and activation of CTSL-mediated degradation of 53BP1.
Importantly, cells that are allowed to re-enter the cell cycle revert
to a cycling phenotype, with upregulation of BRCA1 and cessation of CTSL-mediated degradation of 53BP1. These results suggest that BRCA1 and 53BP1 play an important role in replicating
cells, but seem to be dispensable in non-dividing cells.
An important question is why growth-arrested cells activate
CTSL-mediated degradation of 53BP1. Based on previous studies showing that 53BP1 plays a major role in the genomic instability that characterizes BRCA1-deficient cells,1-5 it is tempting
to speculate that a scenario in which BRCA1 is downregulated,
keeping high levels of 53BP1, would be detrimental for the cells.
Figure 6. Transcripts levels of BRCA1, CTSL, and 53BP1 in growth-arrested
and cycling breast cancer cells. (A) Quantitation of BRCA1 transcripts levels by qRT-PCR in breast cancer cells (MCF7) either growing asynchronously, growth arrested by serum deprivation (starved), or released from
the growth arrest by serum supplementation. Relative expression is
compared in all conditions between CTSL-proficient (shSCR) and CTSLdeficient (shCTSL) cells. (B) Quantitation of CTSL transcripts levels as in
(A). (C) Quantitation of 53BP1 transcripts levels as in (A). **Represents
P value of statistical significance (P ≤ 0.05) of that sample compared
with all the other samples in the experiment. The complete statistical
analysis of all the samples under the different conditions is shown in
supplemental information. (D) MCF7 cells growing asynchronously were
incubated in the presence of hydroxyurea (HU 1mM) or vehicle control
(H2O) overnight and processed for western blot to monitor the levels of
CTSL, 53BP1, and BRCA1. Note how HU treatment slightly increases the
levels of 53BP1 and BRCA1.
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that CTSL does not impact on BRCA1 expression during the
cell cycle. In Figure 6B we show the marked depletion of CTSL
transcripts achieved by transduction with the specific shRNA.
Importantly, serum starvation leads to upregulation of CTSL
transcripts, which are downregulated upon re-entry of the cells
into the cell cycle. This is also consistent with the results obtained
in fibroblasts. Lastly, we find that growth arrest of MCF7 cells
by serum starvation does not alter the levels of 53BP1 transcripts
despite the marked downregulation of 53BP1 protein. These
results are consistent with activation of CTSL-mediated degradation of 53BP1 protein upon growth arrest in different cell lines
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of 53BP1 loss provides a new target for the development of therapeutic strategies for specific types of cancers.

Materials and Methods
Cell culture
Human fibroblasts expressing telomerase (BJ + hTERT) and
MCF7 cells were maintained in DMEM supplemented with 10%
FBS, antibiotics, and antimycotics (complete media).
E64 treatment
Cells were incubated with the broad-spectrum cathepsin
inhibitor E-64 (E3132, Sigma-Aldrich) diluted in H2O at a concentration of 10 µM for the whole duration of the experiments.
Ionizing radiation
For assaying IRIF formation, cells were irradiated with
8 Gy and fixed and processed for immunofluorescence 1 h
post-irradiation.
Contact inhibition of fibroblasts
Eight × 106 BJ + hTERT fibroblasts were plated in 100-mM
tissue culture (TC) dishes in complete media. Cells were maintained confluent for 72 h prior to being collected as “contact
inhibited” or plated in complete media at 1 × 106 cells in 100 mM
TC dishes to allow re-entry into the cell cycle. For time point collection, all media, washes, and trypsinized cells were collected by
centrifugation for analysis.
Serum starvation of MCF7 cells
MCF7 cells were plated in DMEM containing 0.1% FBS,
antibiotics and antimycotics (starvation media) and maintained
in this media for 48 h prior to being collected as “serum starved”
or media being refreshed with FBS to a final concentration of
10% to allow re-entry into the cell cycle. For time point collection, all media, washes and trypsinized cells were collected by
centrifugation for analysis.
Immunoblotting
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM
Tris-HCl pH 7.4, 1% NP-40, 0.2% SDS, 0.25% sodium deoxycholate, and 1 mM EDTA) supplemented with HALT protease
and phosphatase inhibitor cocktail (Thermo Pierce). Lysates
were sheared using 10 passes through a 26-gauge needle followed by 10 passes through a 30-gauge needle and sonication for
7 min. Protein concentration was determined using the BioRad
Dc Protein Assay, and 60–80 μg of total protein was separated
by SDS-PAGE on a 4–15% Criterion TGX Gel (Bio-Rad) and
transferred to a nitrocellulose membrane using the Trans-Blot
Turbo system (Bio-Rad). Antibodies used include: Lamin A/C
(sc-20681, SCBT); 53BP1 (H-300: sc-22760, SCBT); RAD51
(H-92: sc-8349, SCBT); BRCA1 (D-9: sc-6954, SCBT); CTSL
(C1391, Leinco); p107 (C-18: sc-318, SCBT); RPA (NA18,
Millipore); and Cyclin A (sc-271682, SCBT); donkey antirabbit HRP-secondary antibody (ab16284, Abcam); bovine
anti-goat HRP-secondary antibody (sc-2352, SCBT); goat antimouse HRP-secondary antibody (31430, Thermo Scientific).
Nitrocellulose membranes were blocked using 3% milk prepared in PBS + 0.1% Tween-20. Antibodies were diluted in 3%
milk prepared in PBS + 0.1% Tween-20, and membranes were
washed 3 times using PBS + 0.1% Tween-20 after both primary
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In fact, MCF7 cells deficient in both BRCA1 and 53BP1 do not
present profound genomic instability.30 However, stabilization
of 53BP1 in BRCA1-deficient cells induces a marked increase in
genomic instability in response to IR or treatment with PARP
inhibitors. These studies suggest that a balance between BRCA1
and 53BP1 is essential for the maintenance of genomic stability.
As such, maintenance of 53BP1 levels in the context of BRCA1
deficiency, or maintenance of BRCA1 levels in the context of
53BP1 deficiency are associated with defects in DNA repair,
genomic instability, and increased cancer incidence.21-25
We envision that a sensor mechanism could potentially activate CTSL-mediated degradation of 53BP1 to mirror the low
levels of BRCA1 in non-cycling cells. Once BRCA1 is upregulated by re-entry into the cell cycle, cells stabilize 53BP1 protein
levels. Thus, it is possible that the downregulation of BRCA1 in
non-cycling cells is triggering the activation of CTSL-mediated
degradation of 53BP1. Although we do not know the nature
of such a “sensing” mechanism, this scenario resembles other
observations made by us in cells subjected to different stresses.
For example, we previously found that depletion of BRCA1
in breast cancer cells activates CTSL-mediated degradation of
53BP1, which, in turn, allows these cells to overcome genomic
instability and growth arrest.30 In addition, we demonstrated
that CTSL-mediated degradation of 53BP1 is also activated
upon depletion of the structural nuclear proteins A-type lamins.28 Interestingly, lamins-deficient cells also downregulate
BRCA1 transcripts and protein levels, thus providing another
scenario in which loss of BRCA1 coincides with degradation of
53BP1 by CTSL.29 Other reports have also shown activation of
CTSL as well as its accumulation in the nucleus in response to
expression of oncogenic Ras, although the degradation of 53BP1
in this context was not tested.33,34 Intriguingly, expression of Ras
inactivates the BRCA1 DNA repair function by dissociating
BRCA1 from chromatin.35
Altogether, the data suggests that this 53BP1 degradation
mechanism is activated under different stress conditions, and
that in many cases the process is associated with loss of BRCA1
function. Elucidating the molecular mechanisms responsible for
activating CTSL-mediated degradation of 53BP1 could reveal
new information linking this process with the loss of BRCA1
function. We envision that future studies need to address whether
cancer-related mutations in BRCA1 activate this degradation
pathway,36 which could have important consequences for tumorigenesis. Furthermore, given that levels of 53BP1 have been linked
to increased species lifespan,37 understanding the regulation of
53BP1 levels will be relevant for aging. Overall, our findings support an important role for CTSL not only in the regulation of
53BP1 stability in tumor cells, but also as a regulator of protein
stability during growth arrest in both normal and tumor cells.
In addition, our studies identify CTSL-mediated degradation
of 53BP1 as a mechanism activated in non-cycling cells, which
interestingly is exploited by BRCA1-deficient tumor cells to
reduce genomic instability and ensure proliferation and viability.30 Furthermore, levels of CTSL inversely correlate with levels
of 53BP1 in breast cancers with the poorest prognosis, such as
triple-negative and BRCA1-mutated. Therefore, this mechanism
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Quantitative reverse-transcription PCR
RNA was purified from cell pellets using the Bio-Rad Aurum
Kit. cDNA was generated by reverse transcription of 750 ng total
RNA using Bio-Rad iScript. qRT-PCR was performed using the
7900HT Fast Real-Time PCR system (Applied Biosystems) with
the Taqman® Universal PCR Master Mix and Taqman® probe
assays targeting HsBRCA1 (Hs01556193_m1), HsTP53BP1
(Hs00996818_m1), HsCTSL (Hs00377632_m1), and HsPPIB
(Hs00168719_m1) according to the manufacturer’s directions.
Reactions were performed in triplicate and target gene and
endogenous controls were amplified in the same plate. Relative
quantitative measurements of target genes were determined by
using ΔCt calculations.
Viral transduction
Lentiviral transductions were performed as described.27 Briefly,
293T cells were transfected with viral packaging (pHR’8.2ΔR)
and envelope plasmids (p-CMV-VSV-G) along with the vector
containing the shRNA of interest (shscramble or shSCR and
shCTSL). After 48 h, virus-containing media was harvested
to infect target cells (MCF7). Following a 4 h infection, cells
were allowed to recover for 48 h and selected with puromycin.
Viral envelope and packaging plasmids were gifts from Sheila
Stewart (Washington University). shRNAs were obtained from
Sigma-Aldrich.
Cathepsin L activity
Cathepsin L and total Cathepsin activity was measured by using
the fluorogenic substrate Z-Phe-Arg-AMC from the InnoZyme™
Cathepsin L Activity Kit (EMD Chemicals) following the manufacturer’s instructions. Briefly, 106 cells were lysed in Lysis Buffer
(400 mM Na phosphate buffer pH 6, 75 mM NaCl, 4 mM EDTA,
0.25% Triton X-100). One hundred µg of protein extract were
used per sample. Samples were measured in duplicate. Cleaved
Z-Phe-Arg-AMC substrate was detected by fluorescence emission
(Exc. max: 360 nm; Emi. max: 460 nm). Cathepsin L activity
was determined in the presence of CA 074, a specific Cathepsin B
inhibitor. As a negative control, the Cathepsin L inhibitor Z-FY(tbut)-DMK was used. Total cysteine activity was determined as the
cleavage of the substrate in the absence of inhibitors.
Statistical analysis
For all the experiments, a “2-tailed” Student t test was used
to calculate statistical significance of the observed differences.
Microsoft Excel v.2010 was used for the calculations. In all cases,
differences were considered statistically significant when P <
0.05. For some figures the 95% confidence interval based on an
exact binomial distribution was calculated to determine significant differences among samples.
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and secondary antibody incubations. Membranes were developed
using Thermo Pierce ECL (Fisher).
Immunofluorescence
Cells growing on coverslips were processed directly for IF,
or irradiated with 8 Gy and processed 1 h post-irradiation for
53BP1, or 4 h post-irradiation for BRCA1. For immunofluorescence of 53BP1, cells were fixed in 3.7% formaldehyde + 0.2%
Triton-X 100 in PBS for 10 min at RT, and blocked for 1 h at
37 °C in 2% BSA/0.1% Triton-X100 in PBS. Incubations with
53BP1 antibody (1:1000, NB100–304, Novus) and Alexa Fluor
488 goat anti-rabbit (1:1000, A11008, Invitrogen) secondary
antibody were performed for 1 h at 37 °C. Washes were performed in PBS and slides were counterstained with DAPI in
Vectashield (H-1200, Vector Labs). Microscopy and photo capture was performed on a Leica DM5000 B microscope using 63×
or 100× oil objective lenses (NA 1.4 and 1.3, respectively) with a
Leica DFC350FX digital camera and the Leica Application Suite
(Version 4.1.0).
BRCA1 immunofluorescence was performed following a protocol from the Fernandez–Capetillo laboratory. Briefly, cells were
washed twice with PBS, and incubated in CSK I buffer (10 mM
PIPES pH6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2,
1 mM EGTA, and 0.5% Triton X-100) for 5 min. Coverslips
were washed 5 times with cold PBS and fixed in modified STF
buffer (150 mM 2-Bromo-2-nitro-1,3-propanediol, 108 mM diazolidinyl urea, 10 mM Na citrate, and 50 nM EDTA pH 5.7)
for 30 min at RT. Coverslips were then washed twice with cold
PBS and permeabilized (PB buffer: 100 mM Tris-HCl pH 7.4, 50
mM EDTA pH 8.0, and 0.5% Triton X-100) for 15 min at room
temperature followed by 2 washes in PBS. Blocking, antibody
staining, and mounting were performed as described above, with
BRCA1 antibody (sc-6954, Santa Cruz) diluted at 1:200 and
Alexa Fluor 594 goat anti-mouse secondary antibody (A11005,
Invitrogen) diluted at 1:1000.
Fluorescence intensity was measured using ImageJ.
Measurements were taken individually for each cell, as well as for
a small adjacent area to account for background. The corrected
total cell fluorescence (CTCF) was obtained by subtracting the
product of the cell’s area and the mean fluorescence of the background, from the integrated density of the target cell, following
the equation: CTSF = integrated density – (mean background
fluorescence × area of cell).
Analysis of cell cycle profile
Cells were collected from asynchronous culture, contactinhibited culture (fibroblasts), serum-starved culture (MCF7),
or after re-entry into the cell cycle at various time points. Cell
pellets were washed with PBS once and suspended in 500 μl PBS
prior to the dropwise addition of 4.5 ml ice-cold 70% ethanol
while being vortexed at 600 rpm to fix. The cell suspension was
stored at 4 °C until analysis. Fixed cells were pelleted at 1000 ×
g, washed with PBS, and suspended in 1 ml propidium iodide
staining solution (400 μg /ml). Cells were incubated in the staining solution for 15 min at 37 °C. Stained cells were analyzed for
fluorescent DNA content using the Nexcelom Cellometer Vision
CBL, and cell cycle profiles were created by the program Fcs
Express 4 Research Edition.
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